Obesity-related hypertension represents a common clinical condition characterised by complex pathophysiological and therapeutic features. From a pathophysiological view point, results of experimental and animal studies have led to the hypothesis that neurogenic mechanisms participate in the development and progression of the disease. The hypothesis is based on the evidence that metabolic (i.e. insulin-resistance) and neural (sympathetic activation) alterations frequently co-exist in the obese hypertensive patient and that they reciprocally potentiate each other. From a therapeutic view point, the 2007 European Society of Hypertension/European Society of Cardiology emphasised the importance in this clinical condition of treatment not only through antihypertensive drugs but also via lifestyle changes and drug-induced interventions that reduce body weight. The four Rimonabant In Obesity (RIO) studies have shown that rimonabant can decrease body weight. A recent meta-analysis, based on the RIO results, showed that rimonabant, particularly in obese hypertensive patients, can also decrease - although modestly (2.8 mmHg for systolic and 2.2 mmHg for diastolic) - blood pressure. These effects, which appear to be triggered by the weight reduction induced by the drug, are clinically relevant because they contribute favourably to lower the elevated cardiovascular risk profile of the obese hypertensive patient. © 2008 The Authors. Journal compilation © 2008 Blackwell Publishing.

Grassi, G., QUARTI TREVANO, F., Seravalle, G., Arenare, F., Brambilla, G., Mancia, G. (2008). Blood pressure lowering effects of Rimonabant in obesità-related hypertension. JOURNAL OF NEUROENDOCRINOLOGY, 20(Suppl. 1), 63-68 [10.1111/j.1365-2826.2008.01688.x].

Blood pressure lowering effects of Rimonabant in obesità-related hypertension

GRASSI, GUIDO;QUARTI TREVANO, FOSCA ANNA LUISA;ARENARE, FRANCESCA;MANCIA, GIUSEPPE
2008

Abstract

Obesity-related hypertension represents a common clinical condition characterised by complex pathophysiological and therapeutic features. From a pathophysiological view point, results of experimental and animal studies have led to the hypothesis that neurogenic mechanisms participate in the development and progression of the disease. The hypothesis is based on the evidence that metabolic (i.e. insulin-resistance) and neural (sympathetic activation) alterations frequently co-exist in the obese hypertensive patient and that they reciprocally potentiate each other. From a therapeutic view point, the 2007 European Society of Hypertension/European Society of Cardiology emphasised the importance in this clinical condition of treatment not only through antihypertensive drugs but also via lifestyle changes and drug-induced interventions that reduce body weight. The four Rimonabant In Obesity (RIO) studies have shown that rimonabant can decrease body weight. A recent meta-analysis, based on the RIO results, showed that rimonabant, particularly in obese hypertensive patients, can also decrease - although modestly (2.8 mmHg for systolic and 2.2 mmHg for diastolic) - blood pressure. These effects, which appear to be triggered by the weight reduction induced by the drug, are clinically relevant because they contribute favourably to lower the elevated cardiovascular risk profile of the obese hypertensive patient. © 2008 The Authors. Journal compilation © 2008 Blackwell Publishing.
Articolo in rivista - Articolo scientifico
blood pressure; obesity; Cannabinoids; Pyrazoles; Antihypertensive Agents; Down-Regulation; Animals; Piperidines; Hypertension; Sympathetic Nervous System; Humans
English
2008
20
Suppl. 1
63
68
none
Grassi, G., QUARTI TREVANO, F., Seravalle, G., Arenare, F., Brambilla, G., Mancia, G. (2008). Blood pressure lowering effects of Rimonabant in obesità-related hypertension. JOURNAL OF NEUROENDOCRINOLOGY, 20(Suppl. 1), 63-68 [10.1111/j.1365-2826.2008.01688.x].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/13167
Citazioni
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
Social impact